Navigation Links
Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
Date:5/5/2008

Study represents first inclusion of Volcano Revolution(R) 45 MHz IVUS Imaging Catheter in large-scale pharmaceutical plaque progression trial.

SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading manufacturer and developer of intravascular ultrasound (IVUS), functional measurement (FM) and Optical Coherence Tomography (OCT) products designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today participation in SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN). This marks the first major pharmaceutical trial allowing physicians to use the Volcano Revolution(R) 45 MHz IVUS Imaging catheter as part of the protocol.

SATURN is a 104-week, parallel-group, multicentre, double-blind, Phase IIIb intravascular ultrasound (IVUS) imaging study of approximately 1,300 patients at 170 centres worldwide. This study by AstraZeneca is designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression of atherosclerosis in high risk patients. SATURN will compare the effects of these two statins on the ability to decrease progression or induce regression of atherosclerosis, the main cause of cardiovascular disease, following two years of treatment in patients with coronary artery disease.

The SATURN study is chaired by Steve Nissen, M.D., with Steve Nichols, M.D. from the Cleveland Clinic Core Lab as the principle investigator. Under this protocol, physicians enrolling patients may select the Volcano Revolution(R) IVUS catheters as their IVUS catheter of choice.

About Volcano Corporation

Volcano Corporation (NASDAQ: VOLC) offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart diseases and guide optimal therapies. The company's intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options such as VH(TM) tissue characterization and ChromaFlo(R). Internal DICOM networking provided by DICOM by Merge. Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra high-resolution Optical Coherence Tomography systems and catheters. Currently, more than 3,200 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company's website at http://www.volcanocorp.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding Volcano's business that are not historical facts may be considered "forward-looking statements," including statements regarding the company's success and timing of product development and new product introductions, and market penetration, conditions and expectations. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks and uncertainties, which may cause Volcano's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted are detailed in the company's annual report on Form 10-K, quarterly report on Form 10-Q, and other filings made with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Volcano undertakes no obligation to update any forward- looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.


'/>"/>
SOURCE Volcano Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Volcano Sponsors First Study Designed to Determine if IVUS Can Identify Patients at Risk for Stent Thrombosis and to Demonstrate the Benefit of IVUS Guidance for Procedural Outcome
2. Anesiva Announces Publication of Phase 3 Zingo(TM) Data in the Journal Pediatrics
3. ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
7. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
8. XTENT Announces First Quarter 2008 Financial Results
9. Neuralstem Announces Issuance of Core Technology Patent in Europe
10. ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment
11. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017  Bioness, Inc., the ... today announced the first series of successful StimRouter Neuromodulation ... Radboud University Medical Center (Nijmegen, Netherlands ... Cork, Ireland ), and Kliniek Park Leopold ... successful launch continuing, Bioness plans to further support clinicians ...
(Date:2/22/2017)... NEW YORK , February 22, 2017 ... half of the 50 states in the U.S. have now legalized ... Brazil , Canada , ... , Portugal , Uruguay ... steps to legalize or decriminalize cannabis in the last two years. ...
(Date:2/22/2017)... Nordic Nanovector ASA (OSE: NANO), a biopharmaceutical company focusing on ... will announce its fourth quarter and full year 2016 results on ... ... take place at 8:30 am CET at: Thon Hotel ... The presentation will be recorded as a webcast and will be ...
Breaking Medicine Technology:
(Date:2/22/2017)... GA (PRWEB) , ... February 22, 2017 , ... Super-Sod ... 25 and 26 event in Athens, Georgia. , A shift from Super-Sod’s simple Athens ... in Georgia. , For the booth, grass seed plant manager Chris Roquemore constructed furniture ...
(Date:2/22/2017)... ... ... BrightStar Care Charleston , a home care and medical staffing agency, will ... on Aging’s Senior Expo on Thursday, March 23, 2017, at the Omar Convention ... our community. We are thrilled to participate in this event because we believe it ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... solutions for supply chain management (SCM) and spend management, today announced that Keppel ... save time, and simplify expense tracking. , “We are excited to announce ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... introduced five new hospital-grade power extension cords that meet the most current standards. ... the 2012 edition of the National Fire Protection Association (NFPA) 101 – Life ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have been diagnosed ... surgery, treatment, therapy and management. Regular exercise in proper environments has been shown ... their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic HydroWorx ...
Breaking Medicine News(10 mins):